Literature DB >> 16091752

Inhibition of clonogenic tumor growth: a novel function of Smac contributing to its antitumor activity.

Meike Vogler1, Stavros Giagkousiklidis, Felicitas Genze, Juergen E Gschwend, Klaus-Michael Debatin, Simone Fulda.   

Abstract

While second mitochondria derived activator of caspase (Smac) has been described to sensitize for apoptosis, its effect on cell viability in the absence of apoptotic stimuli has remained unclear. Here, we report that Smac inhibits clonogenic tumor growth by blocking random migration and proliferation and by enhancing apoptosis in a cell density and cell type dependent manner in SH-EP neuroblastoma cells. Inhibition of clonogenic survival by overexpression of full-length or processed Smac strictly depended on low cell density, and was reversible by replatement at high density. We discovered that Smac inhibits cell motility and random migration at low cell density. In addition, Smac enhanced apoptosis and inhibited protein, but not mRNA expression of XIAP, survivin and other short-lived proteins (FLIP, p21), indicating that Smac may globally inhibit protein expression. Also, Smac inhibited proliferation and increased polynucleation with no evidence for polyploidy, cell cycle arrest or senescence indicating that Smac impaired cell division. Interestingly, inhibition of clonogenic capacity by Smac occurred independent of its apoptosis promoting activity. By demonstrating that Smac restrains clonogenic tumor growth, our findings may have important implications for control of tumor growth and/or its metastatic spread. Thus, Smac agonists may be useful in cancer therapy, for example, for tumor control in minimal residual disease. Oncogene (2005) 24, 7190-7202. doi:10.1038/sj.onc.1208876; published online 8 August 2005. Oncogene (2005) 24, 7190-7202. doi:10.1038/sj.onc.1208876; published online 8 August 2005.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16091752     DOI: 10.1038/sj.onc.1208876

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  11 in total

1.  Direct ribosomal binding by a cellular inhibitor of translation.

Authors:  Daniel A Colón-Ramos; Christina L Shenvi; Douglas H Weitzel; Eugene C Gan; Robert Matts; Jamie Cate; Sally Kornbluth
Journal:  Nat Struct Mol Biol       Date:  2006-01-22       Impact factor: 15.369

2.  Protein kinase D2 is a novel regulator of glioblastoma growth and tumor formation.

Authors:  Ninel Azoitei; Alexander Kleger; Nina Schoo; Dietmar Rudolf Thal; Cornelia Brunner; Ganesh Varma Pusapati; Alina Filatova; Felicitas Genze; Peter Möller; Til Acker; Rainer Kuefer; Johan Van Lint; Heinrich Baust; Guido Adler; Thomas Seufferlein
Journal:  Neuro Oncol       Date:  2011-07       Impact factor: 12.300

3.  Sildenafil triggers tumor lethality through altered expression of HSP90 and degradation of PKD2.

Authors:  Lu Chen; Yang Liu; Alexander Becher; Kristina Diepold; Evi Schmid; Adrian Fehn; Cornelia Brunner; Arefeh Rouhi; Gabriela Chiosis; Marcus Cronauer; Thomas Seufferlein; Ninel Azoitei
Journal:  Carcinogenesis       Date:  2020-10-15       Impact factor: 4.944

4.  PQJS380: a novel lead compound to induce apoptosis in acute lymphoblastic leukemia cells.

Authors:  Xiaohui Zhu; Li Chen; Sheng Jiang; Chun Chen; Yiwu Yao; Dong Chen; Hongman Xue; Jingxuan Pan
Journal:  Cancer Biol Ther       Date:  2013-11-19       Impact factor: 4.742

5.  Mesothelin-induced pancreatic cancer cell proliferation involves alteration of cyclin E via activation of signal transducer and activator of transcription protein 3.

Authors:  Uddalak Bharadwaj; Min Li; Changyi Chen; Qizhi Yao
Journal:  Mol Cancer Res       Date:  2008-11       Impact factor: 5.852

6.  hHSS1: a novel secreted factor and suppressor of glioma growth located at chromosome 19q13.33.

Authors:  Katiana S Junes-Gill; Timothy K Gallaher; Zoya Gluzman-Poltorak; Joseph D Miller; Christopher J Wheeler; Xuemo Fan; Lena A Basile
Journal:  J Neurooncol       Date:  2010-07-31       Impact factor: 4.130

7.  Microarray-based cancer prediction using soft computing approach.

Authors:  Xiaosheng Wang; Osamu Gotoh
Journal:  Cancer Inform       Date:  2009-05-26

8.  Differential role of RIP1 in Smac mimetic-mediated chemosensitization of neuroblastoma cells.

Authors:  Sebastian Czaplinski; Behnaz Ahangarian Abhari; Alica Torkov; Dominik Seggewiß; Manuela Hugle; Simone Fulda
Journal:  Oncotarget       Date:  2015-12-08

9.  PKM2 promotes tumor angiogenesis by regulating HIF-1α through NF-κB activation.

Authors:  Ninel Azoitei; Alexander Becher; Konrad Steinestel; Arefeh Rouhi; Kristina Diepold; Felicitas Genze; Thomas Simmet; Thomas Seufferlein
Journal:  Mol Cancer       Date:  2016-01-06       Impact factor: 27.401

10.  STK33 participates to HSP90-supported angiogenic program in hypoxic tumors by regulating HIF-1α/VEGF signaling pathway.

Authors:  Yang Liu; Konrad Steinestel; Arefeh Rouhi; Milena Armacki; Kristina Diepold; Gabriela Chiosis; Thomas Simmet; Thomas Seufferlein; Ninel Azoitei
Journal:  Oncotarget       Date:  2017-08-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.